{"id":1695,"date":"2020-12-01T14:03:00","date_gmt":"2020-12-01T14:03:00","guid":{"rendered":"https:\/\/tris.sambrownprojects.com\/tris-announces-us-district-court-upholds-validity-of-quillivant-xr-patents-rules-teva-infringes-tris-patents\/"},"modified":"2024-06-03T11:09:51","modified_gmt":"2024-06-03T10:09:51","slug":"tris-announces-us-district-court-upholds-validity-of-quillivant-xr-patents-rules-teva-infringes-tris-patents","status":"publish","type":"post","link":"https:\/\/www.trispharma.com\/tris-announces-us-district-court-upholds-validity-of-quillivant-xr-patents-rules-teva-infringes-tris-patents\/","title":{"rendered":"Tris announces US District Court Upholds Validity of Quillivant XR\u00ae Patents; Rules Teva Infringes Tris Patents"},"content":{"rendered":"\r\n

MONMOUTH JUNCTION, December 1, 2020 \/ PRNewswire\/ \u2013 Tris Pharma, Inc. (\u201cTris\u201d), a specialty pharmaceutical company with a robust portfolio of approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, announced the decision by the US District Court for the District of Delaware to uphold the validity of various patents relating to Quillivant XR\u00ae<\/sup> (methylphenidate HCl)<\/p>\r\n\r\n\r\n\r\n

The decision further holds that a generic methylphenidate product proposed by Actavis Laboratories FL, incorporated in its Abbreviated New Drug Application (ANDA) will infringe the asserted Tris patents.  In particular, the Court found that \u201call the asserted claims of the asserted patents before me on remand are not invalid and that Defendants directly infringe, contributorily infringe, and induce the infringement of each of the asserted claims.\u201d  The ruling prevents Activis from launching generic versions of Quillivant XR until the expiration of the patent portfolio providing exclusivity until February 2031. <\/p>\r\n\r\n\r\n\r\n

 \u201cThis is a huge win for Tris and provides for long exclusive life for a key portfolio product. We welcome this decision upholding the validity of the Quillivant XR patents, as it reflects the innovative nature of our LiquiXR\u00ae<\/sup> technology which was used to develop Quillivant XR and our other branded ADHD medications.\u201d said Ketan Mehta, Founder and Chief Executive Officer of Tris Pharma.  \u201cValidation of our intellectual property permits Tris to continue investing in innovation to develop novel treatments that improve patients\u2019 lives.\u201d<\/p>\r\n\r\n\r\n\r\n

Quillivant XR is approved for treatment of ADHD in people 6 years and older. See Approved Use and Important Safety Information, including Boxed Warning about Abuse and Dependence, below.<\/p>\r\n\r\n\r\n\r\n

About Tris Pharma<\/strong><\/p>\r\n\r\n\r\n\r\n

Tris Pharma is a New Jersey-based specialty pharmaceutical company focused on the development and commercialization of innovative medicines that address unmet patient needs. Tris has used its LiquiXR technology platform to develop a portfolio of differentiated solid and liquid medications as well as a robust pipeline which spans multiple therapeutic categories, and its technology has formed the basis for numerous mutually value-adding development partnerships. Within the United States Tris promotes its portfolio of ADHD products (described at <\/a>www.TrisADHD.com<\/a>) using its pediatric and CNS-focused sales force. For more information, please visit www.trispharma.com<\/a>.<\/p>\r\n\r\n\r\n\r\n

APPROVED USE<\/strong><\/p>\r\n\r\n\r\n\r\n

Quillivant XR is central nervous system  stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years and older. Quillivant XR may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD.<\/p>\r\n\r\n\r\n\r\n

It is not known if Quillivant XR is safe and effective in children under 6 years of age.<\/p>\r\n\r\n\r\n\r\n

IMPORTANT SAFETY INFORMATION<\/strong><\/p>\r\n\r\n\r\n\r\n

Quillivant XR is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep Quillivant XR in a safe place to prevent misuse and abuse. Selling or giving away Quillivant XR may harm others and is against the law.<\/strong> Tell your doctor if you or your child have (or have a family history of) ever abused or been dependent on alcohol, prescription medicines, or street drugs.<\/p>\r\n\r\n\r\n\r\n

Quillivant XR should not be taken if you or your child <\/strong>are allergic to methylphenidate hydrochloride, or any of the ingredients in Quillivant XR, or are taking or have taken within the past 14 days an antidepression medicine called a monoamine oxidase inhibitor or MAOI.<\/p>\r\n\r\n\r\n\r\n

The following have been reported with the use of methylphenidate hydrochloride and other stimulant medicines:<\/strong><\/p>\r\n\r\n\r\n\r\n